Paras Healthcare IPO (₹660-693): June-quarter profit ₹49.7 crore, but at about 160 times FY26 profit the price is full. Should you subscribe?
Paras Healthcare made a profit of ₹49.7 crore in the June 2026 quarter, against a small loss a year earlier. At the top of the price band the company is valued at about ₹7,500 crore. That is roughly 160 times its FY26 profit, and the number is higher than for all nine listed hospital peers in the offer document. Anchor funds have already put in ₹652.5 crore. Should you apply?
Paras Healthcare (IPO opens 21 October, closes 23 October; listing expected 28 October on BSE and NSE) - Price band: ₹660 to ₹693 a share (face value ₹1) - Market cap at the ₹693 upper band: about ₹7,498 crore after the new shares are issued (my calculation: 10.82 crore shares after the issue × ₹693; the market cap counts all shares, not only the ones sold in the IPO). At ₹660 it is about ₹7,141 crore - P/E: about 160 times FY26 profit before the issue (₹693 ÷ basic earnings per share of ₹4.34). On the larger share count after the issue, it is about 171 times. The listed hospital peers in the offer document trade at 43 to 116 times, with an average of 68 - Subscription, listing price and live share price: not known yet, because the shares have not started trading
This article is written on anchor day. The company is not listed, so there is no market price. The figures come from the Red Herring Prospectus (RHP) dated 14 October 2026, unless I say otherwise.
What Paras Healthcare does
Paras Healthcare runs eight hospitals under the "Paras Health" brand. They have 2,211 beds in total (1,502 are staffed and working beds) in Gurugram, Panchkula, Patna, Darbhanga, Udaipur, Ranchi, Srinagar and Kanpur. The company says it is one of the largest hospital operators in North India, Bihar and Jharkhand.
- The company was incorporated on 21 December 1987 as "Arbian Frozen Foods Private Limited". It later became a hospital company. Its first hospital opened in Gurugram in 2006 with 200 beds. - 74% of revenue comes from six big specialities: heart, cancer, brain and nerves, bones, stomach and liver, and kidney care. - 70% of revenue comes from smaller "tier 2" cities. Gurugram is the one big-city hospital. - The company is in a large market. The offer document quotes a CRISIL report that puts India's healthcare delivery market at about ₹7.0 trillion in FY25.
The latest results
All figures are restated consolidated numbers from the RHP, in ₹ crore.
FY24 FY25 FY26 June 2025 quarter June 2026 quarter ------------------ Revenue from operations 1,129 1,294 1,606 368 470 EBITDA 154 156 336 66 113 EBITDA margin 13.4% 11.9% 20.6% 17.7% 23.7% Profit before tax 6.6 -50.0 76.0 5.8 48.1 Profit after tax (PAT) -15.3 -58.0 43.8 -1.0 49.7
- June 2026 quarter revenue grew 27.7% over the same quarter a year ago. FY26 revenue grew 24.1%. - EBITDA more than doubled in FY26 (up 114%) and rose 71% in the June quarter. - Profit is very recent. The company made losses in FY24 and FY25. FY26 is its first full year with a profit. - The June quarter profit after tax (₹49.7 crore) is higher than profit before tax (₹48.1 crore) because of a net tax credit of about ₹1.6 crore. So the quarter's profit looks a little better than the business earned.
Why did profit jump? More beds filled. Bed occupancy (the share of working beds in use) rose to 69.7% in the June 2026 quarter from 56.8% a year earlier. The two newest hospitals are still filling up: Kanpur ran at 31% and Srinagar at 36% in FY26.
FY24 FY25 FY26 June 2026 quarter --------------- Bed occupancy 52.5% 50.8% 61.8% 69.7% Revenue per occupied bed per day (ARPOB) ₹44,306 ₹48,089 ₹47,398 ₹49,352 Gurugram occupancy 74.9% 74.3% 83.9% 89.1% Gurugram ARPOB ₹61,983 ₹68,695 ₹70,926 ₹74,912
Filling beds was a major driver of growth, not higher prices per bed (patient mix and outpatient work also play a part). Revenue per bed was flat to slightly lower in FY26 than in FY25. The June 2026 quarter was the first time it rose again.
Profit against cash: where the debt hurts
The company must pay for hospital equipment and the interest on its loans. That is why EBITDA of ₹336 crore turned into profit before tax of only ₹76 crore in FY26.
- Depreciation: ₹143.6 crore in FY26. - Finance cost (interest, including interest on leased buildings): ₹116.0 crore in FY26. - Profit before interest and tax was about ₹192 crore (profit before tax plus finance cost). That is about 1.7 times the finance cost. This is my rough measure, not the company's own interest-cover ratio, and the finance cost includes interest on leased buildings.
Cash from operations was ₹163.5 crore in FY26, well above the profit of ₹43.8 crore. But the company spent ₹169.4 crore on equipment and buildings in the same year, so almost nothing was left over.
₹ crore FY24 FY25 FY26 ------------ Profit after tax -15.3 -58.0 43.8 Cash from operations 92.5 86.2 163.5 Capital spending 197.6 136.7 169.4
Debt. At 31 March 2026 the company owed ₹854 crore to banks and lenders (₹454 crore long term and ₹400 crore short term). It also had ₹540 crore of lease liabilities for hospital buildings. Cash and bank balances were about ₹303 crore. The RHP shows debt-to-equity of 3.53 times including leases, and 2.16 times excluding them. For June 2026 the figures are 3.21 and 2.00. Debt is high for a company with this much profit.
Assets. Total assets were ₹2,071 crore. Hospital equipment and other fixed assets were ₹674 crore. Leased buildings (right-of-use assets) were ₹531 crore. Work in progress was ₹29 crore.
Do customers pay on time?
Trade receivables are the money patients' payers (insurers, government schemes and others) owe the hospital. Borrowings are a different thing: money the hospital owes lenders.
₹ crore 31 Mar 2024 31 Mar 2025 31 Mar 2026 30 Jun 2026 --------------- Net trade receivables 156 235 350 448 As days of revenue (my calculation, year-end balance ÷ revenue per day) 51 66 79 87 Trade payables (what the hospital owes its suppliers) 137 191 208 not shown separately in the sources I used
- Receivables grew faster than revenue for three years. They rose by ₹100 crore in the June 2026 quarter alone. - Rough estimate: supplier dues of ₹208 crore equal about 47 days of FY26 revenue, while customer dues equal about 79 days. This compares year-end balances with revenue, not purchases, so treat the gap as a guide only. A gap like this needs cash, and the company borrows to fill it. - Of the ₹509 crore gross receivables in June 2026, ₹91 crore was more than a year old, including ₹38 crore over three years old and fully provided for. - The company has set aside ₹61.5 crore for money it may not recover (June 2026). - The RHP's cash flow shows the same story: the rise in receivables used ₹125 crore of cash in FY26 and ₹101 crore in the June 2026 quarter.
The reason is the payer mix. Government schemes and public-sector payers now bring 43.6% of revenue, up from 29.8% in FY24. Self-paying patients fell from 40.6% to 31.3%. Government payers often pay slowly.
The price: expensive on profit, less so on operating profit
At the upper band the offer document's own peers look like this (peer prices of 5 October 2026, FY26 earnings):
Company P/E (times) Return on net worth --------- Krishna Institute of Medical Sciences 116.4 11.0% Aster DM Healthcare (Quality Care) 91.9 9.7% Manipal Health Enterprises 87.0 12.4% Global Health (Medanta) 64.5 15.2% Max Healthcare 62.1 14.3% Apollo Hospitals 59.4 22.0% Fortis Healthcare 55.4 11.1% Narayana Hrudayalaya 43.4 19.7% Jupiter Lifeline 42.9 13.4% Paras Healthcare at ₹693 about 160 13.0%
- The peer list and figures are as listed in the RHP. The Paras P/E is my own calculation, because the RHP leaves the price band blank in its table. - Paras's FY26 return on net worth of 13.0% is in line with peers. Its three-year weighted return on net worth is negative (-1.1%) because of the FY24 and FY25 losses. - On annualised June-quarter profit (₹49.7 crore × 4), the P/E would be about 38 times. This is only an illustration, not a forecast: it assumes four identical quarters. About ₹1.6 crore of it came from a tax credit. - On my own calculation, enterprise value (shares before the issue × ₹693, plus 31 March 2026 debt and leases, less cash and bank balances) is about 24 times FY26 EBITDA. The RHP gives its peers a range of 23 to 41 times. EBITDA looks fairly priced; profit does not, because interest and depreciation take so much of it.
Who is selling, and who bought earlier
- Fresh issue: ₹500 crore (72.15 lakh new shares). The company gets this money. - Offer for sale (OFS): ₹950 crore (about 1.37 crore shares). The company does not get this money. Promoter Dr. Dharminder Kumar Nagar sells ₹300 crore. Commelina Ltd, an affiliate of the private equity firm Creador, sells ₹650 crore. - Commelina's average cost is ₹114.15 a share. The promoter's average cost is ₹2.35 a share. - In April 2025, 360 ONE funds and Axis New Opportunities AIF bought 74.9 lakh shares at ₹237 a share (₹177 crore in total). The upper band is 2.9 times that price, about 18 months later.
Holder Before the issue After the issue (my calculation, ₹693, full subscription) --------- Dr. Dharminder Kumar Nagar (promoter) 72.8% about 63.9% Commelina Ltd 16.4% about 6.7% Other existing holders 10.8% about 10.0% New public shareholders none about 19.3%
(The percentages add up to about 99.9% because of rounding.)
What the fresh money is for
- ₹320.9 crore: repay loans of the company. - ₹54.1 crore: put into its subsidiary Plus Medicare Hospitals (which runs the Srinagar hospital), to repay that subsidiary's loans. - The rest: general corporate purposes (capped at 25% of the fresh issue).
So about ₹375 crore, three quarters of the fresh issue, goes to loans. This should cut the interest bill. Nothing from the issue is earmarked for new beds. Expansion plans (Gurugram second hospital and a Ludhiana hospital, reported at about 300 and 500 beds, and a target of 3,011 beds by March 2028) are to be done on long-term leases, where the building owner builds the shell and Paras buys the equipment.
The anchor investors
On 19 October, the company allotted 94.16 lakh shares at ₹693 to anchor investors, raising ₹652.5 crore.
- PTI reports 39 funds. Kotak Neo counts 21 institutional investors. The two counts may differ because one fund house can have several funds. - Nine domestic mutual funds took 55.55 lakh shares worth about ₹385 crore, across 24 schemes (Kotak Neo). - Named in reports: SBI Mutual Fund, HDFC Mutual Fund, ICICI Prudential Mutual Fund, Kotak Mutual Fund, Whiteoak Capital Mutual Fund, Abu Dhabi Investment Authority, BlackRock and Eastspring Investments. One report also names Government Pension Fund Global. - The reports I could read do not give the amount for each named fund. So I do not state one.
This is a recognisable anchor book with several large mutual funds and sovereign investors. That shows institutions are interested; it does not prove the price is attractive for you, because they may invest for different time horizons. Anchors paid the upper-band price. The usual lock-in rule is that half of the anchor shares cannot be sold for 30 days and the rest for 90 days after allotment. If allotment happens on 26 October as expected, the dates would be around late November 2026 and late January 2027, but the exact dates depend on the final allotment. I have not seen the company's own dates.
Management and risks
- Promoter: Dr. Dharminder Kumar Nagar, 56, Managing Director. He has an MBBS from the University of Mysore, an M.Phil in hospital and health systems management from BITS Pilani and a Harvard course. He has been with the company since 2003 and has more than 22 years in healthcare. He bought his shares from the earlier owners in 2003 and 2005, so he is not the original promoter. He was re-appointed Managing Director for five years from 1 April 2027. - Dr. Kapil Garg, Whole-time Director, joined in 2012. Earlier he worked at Escorts, Apollo, Fortis and Columbia Asia. The chairman is Saurabh Sood. Kabir Thakur sits on the board for Commelina. - Debt: high, as shown above. The IPO repays about ₹375 crore of it. - Slow payers: receivables took ₹100 crore of cash in one quarter, and government payers are 44% of revenue. - New hospitals: Kanpur and Srinagar are still far from full. Their losses fed the FY25 loss. - Court cases: the RHP lists a criminal complaint filed in 2019 in Darbhanga against the hospital and the Managing Director over alleged negligence. It also lists a January 2026 police case in Gurugram against the company and some doctors, over a patient's death. The company has asked the High Court to cancel that case. Both are pending. - Short profit history: one profitable year, plus one profitable quarter that includes a tax credit.
GMP and issue details
- Lot size: 21 shares (₹14,553 at the upper band). Retail investors can apply for 1 to 13 lots. - Issue size: ₹1,450 crore. Not more than 75% for institutions, not less than 15% for non-institutional investors and not less than 10% for retail. - Allotment is expected on 26 October and listing on 28 October. - Grey market premium (GMP): reports vary from about ₹77 to ₹92 a share. This is an unofficial number and can change quickly or disappear. - Management guidance: the RHP does not give revenue or profit targets. Only the bed-expansion plans above are stated.
What to weigh
The business is improving fast: revenue up 28%, occupancy at 70% and operating margin at 24%. Big mutual funds and sovereign investors are in the anchor book. The price asks you to pay for that improvement in advance. At about 160 times FY26 profit, the stock needs profit to grow several times over before the price looks normal, and the company must do that while carrying a lot of debt and with customers taking longer to pay.
Key point In my view, Paras Healthcare is a fast-improving hospital chain that is priced as if the improvement is already done. Look at how much of the ₹1,450 crore goes to the sellers (₹950 crore) and at the 87 days it takes customers to pay, before the headline profit growth.
Whether to apply depends on your view of that growth and your comfort with a company that has had only one profitable year. If you apply, note that a target or GMP is no promise. Check the final subscription figures after the issue closes on 23 October.
Note: I am not a SEBI-registered investment advisor. This article is for educational purposes only and is not investment advice. Please consult a registered financial advisor before making investment decisions.
Sources
- https://parashospitals-web.s3.ap-south-1.amazonaws.com/investor-data/October2026/LotlRQkorWo9iWLUuGcN.pdf - https://www.sebi.gov.in/sebidata/commondocs/oct-2026/Paras%20Healthcare%20Limitedp.pdf - https://www.kotakneo.com/news/ipos/paras-healthcare-ipo-652-5-crore-raised-from-anchor-investors/ - https://www.tradingview.com/news/moodys:e318555413d13:0-paras-healthcare-secures-652-cr-from-anchor-investors-ipo-to-open-on-oct-21/ - https://www.chittorgarh.com/ipo/paras-healthcare-ipo/2256/